Last reviewed · How we verify

Lidocaine 1%/Epi 1:200000

Wahba bakhet · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Lidocaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local anesthesia for infiltration, nerve blocks, and topical procedures, Dental anesthesia, Minor surgical procedures requiring local anesthesia.

At a glance

Generic nameLidocaine 1%/Epi 1:200000
Also known asXylocaine 1%/Epi 1:200000
SponsorWahba bakhet
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. The addition of epinephrine (1:200,000 concentration) acts as a vasconstrictor on local blood vessels, which slows the systemic absorption of lidocaine, extends its duration of action at the injection site, and reduces the risk of systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: